Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 10/20 | 0.58 |
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723124 | 0.86 | NPC1 (0.60) | LTA4HNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4724589 | 0.86 | RAB9A (0.60) | LTA4HNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4314798 | 0.83 | LTA4H (0.64) | LTA4HNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL722557 | 0.82 | LTA4H (0.64) | LTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL11029318 | 0.82 | S1PR1 (0.56) | LTA4HNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL28320605 | 0.80 | LTA4H (0.62) | LTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28257875 | 0.80 | LTA4H (0.62) | LTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28362996 | 0.80 | LTA4H (0.62) | LTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL13049175 | 0.79 | LTA4H (0.64) | LTA4HNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL8239613 | 0.79 | LTA4H (0.50) | LTA4HNPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104327006-A | Preparation method of 5-ehtyl-4-formamidooxazole | Hunan huateng pharmaceutical co ltd | 2015-02-04 | — | — | CN | claimed |
| CN-104262281-A | Preparation method of 2-bromo-4(4-ethoxyphenyl) oxazole | Hunan huateng pharmaceutical co ltd | 2015-01-07 | — | — | CN | claimed |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-06-21 | — | — | US | disclosed |
| CN-105753787-B | Tumor-targeting drug Combretastatin A4 derivatives | 南京圣和药业股份有限公司 | 2018-05-15 | — | — | CN | disclosed |
| EP-2999699-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | Agency For Science, Technology And Research (SG) | 2016-03-30 | — | — | EP | disclosed |
| CN-104262281-A | Preparation method of 2-bromo-4(4-ethoxyphenyl) oxazole | Hunan huateng pharmaceutical co ltd | 2015-01-07 | — | — | CN | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | LTA4H 70/4885NPC1 3867/4885RAB9A 2943/4885 |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | LTA4H 2505/4885NPC1 2489/4885RAB9A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.